Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function (REPAIR-IDA)
This study has been completed.
Study NCT00981045   Information provided by Luitpold Pharmaceuticals

First Received on September 21, 2009.   Last Updated on April 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Iron Deficiency Anemia
Impaired Renal Function
Additional conditions recognized in this trial
Anemia
Anemia, Iron-Deficiency
Deficiency Diseases
Renal Insufficiency
More general conditions related to this trial
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Kidney Diseases
Malnutrition
Metabolic Diseases
Nutrition Disorders
Urologic Diseases
Interventions listed in this trial
Ferric Carboxymaltose (FCM)
Iron Sucrose (Venofer)
Additional drug interventions recognized in this trial
Ferric Compounds
Ferric oxide, saccharated
Iron
More general drug interventions related to this trial
Growth Substances
Hematinics
Hematologic Agents
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Sponsors listed in this trial
Luitpold Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services